EarningsSGMO reported a net loss per share of ($0.34), which was higher than the consensus estimate of ($0.26), reflecting financial results that were below market expectations.
Product DevelopmentSangamo is stopping further development of its clinical programs in Fabry disease and CAR-Treg cell therapy and actively seeking collaboration or investment partners in both.
Risk FactorsRisks include clinical development, commercialization, reimbursement, capital markets and dilution, pricing, and business development risk.